From: Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study
Adverse event
n (%)
Patients with any TEAE
83 (68.0)
Nausea
26 (21.3)
Headache
11 (9.0)
Anxiety
8 (6.6)
Constipation
7 (5.7)
Diarrhea